## Alexander T Pearson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8522603/publications.pdf

Version: 2024-02-01

80 papers 3,156 citations

257101 24 h-index 51 g-index

86 all docs 86 docs citations

86 times ranked 4025 citing authors

#	Article	IF	CITATIONS
1	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, 2019, 25, 1054-1056.	15.2	773
2	Pan-cancer image-based detection of clinically actionable genetic alterations. Nature Cancer, 2020, 1, 789-799.	5 <b>.</b> 7	343
3	Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology, 2020, 159, 1406-1416.e11.	0.6	209
4	The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends in Cancer, 2020, 6, 192-204.	3.8	162
5	The impact of site-specific digital histology signatures on deep learning model accuracy and bias.  Nature Communications, 2021, 12, 4423.	5 <b>.</b> 8	111
6	Postnatal exposure to methyl mercury from fish consumption: A review and new data from the Seychelles Child Development Study. NeuroToxicology, 2009, 30, 338-349.	1.4	102
7	Extracellular matrix alignment dictates the organization of focal adhesions and directs uniaxial cell migration. APL Bioengineering, 2018, 2, 046107.	3.3	78
8	Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nature Communications, 2020, $11,363$ .	5 <b>.</b> 8	75
9	Mucoepidermoid Carcinoma. American Journal of Surgical Pathology, 2019, 43, 885-897.	2.1	70
10	Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 2021, 3, e654-e664.	5.9	69
11	Machine Learning–Guided Adjuvant Treatment of Head and Neck Cancer. JAMA Network Open, 2020, 3, e2025881.	2.8	65
12	A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. Journal of Clinical Investigation, 2020, 130, 1405-1416.	3.9	64
13	Patient-derived xenograft (PDX) tumors increase growth rate with time. Oncotarget, 2016, 7, 7993-8005.	0.8	63
14	ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget, 2015, 6, 26633-26650.	0.8	59
15	Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma. Stem Cells, 2019, 37, 257-269.	1.4	58
16	EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells. Cancer Research, 2016, 76, 6396-6409.	0.4	55
17	Identifying predictors of <scp>HPV</scp> â€related head and neck squamous cell carcinoma progression and survival through patientâ€derived models. International Journal of Cancer, 2020, 147, 3236-3249.	2.3	40
18	5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2017, 23, 2516-2527.	3.2	39

#	Article	IF	Citations
19	Wnt–β-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. Nature Immunology, 2021, 22, 471-484.	7.0	39
20	Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS Computational Biology, 2022, 18, e1009822.	1.5	36
21	Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget, 2015, 6, 22822-22835.	0.8	33
22	Artificial Intelligence Can Cut Costs While Maintaining Accuracy in Colorectal Cancer Genotyping. Frontiers in Oncology, 2021, 11, 630953.	1.3	31
23	A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Investigational New Drugs, 2016, 34, 481-489.	1.2	30
24	Deep learning prediction of BRAF-RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Modern Pathology, 2021, 34, 862-874.	2.9	30
25	Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors Journal of Clinical Oncology, 2020, 38, 6516-6516.	0.8	30
26	Therapeutic Inhibition of the MDM2–p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clinical Cancer Research, 2017, 23, 1036-1048.	3.2	27
27	The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death and Disease, 2021, 12, 988.	2.7	27
28	A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment. PLoS Computational Biology, 2018, 14, e1005920.	1.5	26
29	4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22423-22429.	3.3	24
30	Endothelial-derived interleukin-6 induces cancer stem cell motility by generating a chemotactic gradient towards blood vessels. Oncotarget, 2017, 8, 100339-100352.	0.8	24
31	UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. Oral Oncology, 2018, 87, 21-28.	0.8	23
32	Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 1-15.	1.1	19
33	Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. British Journal of Cancer, 2022, 126, 361-370.	2.9	18
34	Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2–p53 Interaction in Mucoepidermoid Carcinoma. Clinical Cancer Research, 2019, 25, 1588-1600.	3.2	17
35	Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial Journal of Clinical Oncology, 2021, 39, 6011-6011.	0.8	17
36	Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 677051.	1.3	16

#	Article	IF	CITATIONS
37	The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2022, 31, 531-548.	1.9	16
38	BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma. Oral Oncology, 2015, 51, 839-847.	0.8	13
39	Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clinical Cancer Research, 2016, 22, 3550-3559.	3.2	13
40	Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. Cancer Letters, 2020, 471, 49-60.	3.2	12
41	Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097411.	1.4	12
42	Academics as leaders in the cancer artificial intelligence revolution. Cancer, 2021, 127, 664-671.	2.0	10
43	Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncology, 2021, 122, 105566.	0.8	10
44	A validated mathematical model of FGFR3â€mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer. Computational and Systems Oncology, 2021, 1, e1019.	1.1	9
45	Modeling head and neck cancer stem cell-mediated tumorigenesis. Cellular and Molecular Life Sciences, 2016, 73, 3279-3289.	2.4	7
46	Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck. Otolaryngology - Head and Neck Surgery, 2017, 157, 995-997.	1.1	7
47	Hyperprogressionâ€"Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer. JAMA Oncology, 2019, 5, 743.	3.4	7
48	COVIDomic: A multi-modal cloud-based platform for identification of risk factors associated with COVID-19 severity. PLoS Computational Biology, 2021, 17, e1009183.	1.5	7
49	Isolation and Characterization of Cancer Stem Cells from Primary Head and Neck Squamous Cell Carcinoma Tumors. Methods in Molecular Biology, 2016, 1395, 241-249.	0.4	6
50	<i>In Silico</i> Models Accurately Predict <i>In Vivo</i> Response for IL6 Blockade in Head and Neck Cancer. Cancer Research, 2020, 80, 1451-1460.	0.4	6
51	Survival of salivary gland cancer stem cells requires mTOR signaling. Cell Death and Disease, 2021, 12, 108.	2.7	6
52	First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers Journal of Clinical Oncology, 2021, 39, 2502-2502.	0.8	6
53	Differentiating low and high grade mucoepidermoid carcinoma of the salivary glands using CT radiomics. Gland Surgery, 2021, 10, 1646-1654.	0.5	6
54	Monitoring Spontaneous Quiescence and Asynchronous Proliferation-Quiescence Decisions in Prostate Cancer Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 728663.	1.8	6

#	Article	IF	CITATIONS
55	A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues. IScience, 2022, 25, 104387.	1.9	6
56	Prognosis and Treatment of Non–Small Cell Lung Cancer in the Age of Deep Learning. JAMA Network Open, 2020, 3, e206368.	2.8	5
57	Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial Journal of Clinical Oncology, 2021, 39, 6048-6048.	0.8	5
58	A robust and interpretable gene signature for predicting the lymph node status of primary <scp>T1</scp> / <scp>T2</scp> oral cavity squamous cell carcinoma. International Journal of Cancer, 2022, 150, 450-460.	2.3	5
59	Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer, 2022, 22, 17.	1.1	5
60	The Endothelin-A Receptor Antagonist Zibotentan Induces Damage to the Nasal Olfactory Epithelium Possibly Mediated in Part through Type 2 Innate Lymphoid Cells. Toxicologic Pathology, 2019, 47, 150-164.	0.9	3
61	Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Network Open, 2022, 5, e227240.	2.8	3
62	Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers Journal of Clinical Oncology, 2022, 40, 2517-2517.	0.8	3
63	Hyperlink-Embedded Journal Articles Improve Statistical Knowledge and Reader Satisfaction. Journal of Graduate Medical Education, 2015, 7, 654-657.	0.6	2
64	<scp>Longâ€term</scp> neck and shoulder function among survivors of oropharyngeal squamous cell carcinoma treated with chemoradiation as assessed with the neck dissection impairment index. Head and Neck, 2021, 43, 1621-1628.	0.9	2
65	Dose and volume de-escalation for HPV-associated oropharyngeal cancer: Long-term follow-up of the OPTIMA trial Journal of Clinical Oncology, 2020, 38, 6575-6575.	0.8	2
66	Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy Journal of Clinical Oncology, 2020, 38, TPS3173-TPS3173.	0.8	2
67	Sampling from single-cell observations to predict tumor cell growth <i>in-vitro</i> and <i>in-vivo</i> . Oncotarget, 2017, 8, 111176-111189.	0.8	2
68	Ovarian cancer through a multi-modal lens. Nature Cancer, 2022, 3, 662-664.	5.7	2
69	Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma Journal of Clinical Oncology, 2021, 39, TPS6094-TPS6094.	0.8	1
70	Is This the Dawn of Precision Oncology in Head and Neck Cancer?. Journal of Clinical Oncology, 2021, 39, 1839-1841.	0.8	1
71	Machine learning guided adjuvant treatment of head and neck cancer Journal of Clinical Oncology, 2020, 38, 6567-6567.	0.8	1
72	The use of artificial intelligence with uncertainty estimation to predict lung cancer relapse from histopathology Journal of Clinical Oncology, 2022, 40, 8549-8549.	0.8	1

#	Article	IF	CITATIONS
73	Nivolumab-based induction chemoimmunotherapy and PD-L1 expression in locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma Journal of Clinical Oncology, 2022, 40, 6075-6075.	0.8	1
74	MATHEMATICAL CHARACTERIZATION OF HETEROGENEITY IN A CANCER STEM CELL DRIVEN TUMOR GROWTH MODEL WITH NONLINEAR SELF-RENEWAL. Journal of Biological Systems, 2021, 29, 27-48.	0.5	0
75	Mathematical predication models to optimize post-treatment surveillance in HPV-associated oropharyngeal cancer Journal of Clinical Oncology, 2021, 39, 6027-6027.	0.8	0
76	Validation of the RSClin risk calculator using the National Cancer Database (NCDB) Journal of Clinical Oncology, 2021, 39, 549-549.	0.8	0
77	Prediction of histologic and molecular subsets of soft tissue sarcoma using deep learning. Journal of Clinical Oncology, 2020, 38, e23529-e23529.	0.8	0
78	Abstract P1-08-21: Assessing the impact of treatment interruptions during neoadjuvant therapy in early stage breast cancer. Cancer Research, 2022, 82, P1-08-21-P1-08-21.	0.4	0
79	Adapting a medical school cancer research education program to the virtual environment Journal of Clinical Oncology, 2022, 40, 11029-11029.	0.8	0
80	Drug response prediction in patient-derived xenografts with data augmentation and multimodal deep learning Journal of Clinical Oncology, 2022, 40, e13572-e13572.	0.8	0